%0 Letter
%T Antiviral activity of theaflavins against Zika virus in vivo and in vitro.
%A Deng X
%A Lv C
%A Wang T
%A Guo J
%A Luo R
%A Qi J
%A Sima M
%A Yue D
%A Gao Y
%J J Infect Chemother
%V 30
%N 6
%D 2024 Jun 29
%M 38036028
%F 2.065
%R 10.1016/j.jiac.2023.11.023
%X BACKGROUND: The prevalence and infection of the Zika virus (ZIKV) have recently posed a major threat to global public health security. However, there is currently a lack of specific vaccines and effective antiviral drugs for ZIKV infection.
METHODS: Theaflavins TF1 and TF2 were selected by evaluating the anti-Zika virus activity of four kinds of theaflavins in vitro. Subsequently, in vivo, we investigated the effects of TF1 and TF2 on weight, survival, tissue viral load, and cytokines in ZIKV-infected mice.
RESULTS: We compared the anti-ZIKV activity of four theaflavins (TFs) in cells and found that TF1 and TF2b significantly inhibited the replication of ZIKV/Z16006 toxic strain in BHK and Vero cells by inhibiting the replication and release of ZIKV, while no similar effects were observed for TF2a and TF3. In vivo assay, we only found that TF2b improved the survival rate of infected mice. In tissues of ZIKV-infected mice, the viral load was higher in spleen and blood, followed by liver, epididymis, and testis, the lowest in muscle. Additionally, TF2b treatment significantly reduced the expression of cytokines (IL-6, IL-1β, TNF-α) and chemokines (CCL2, CCL5, CXCL10) induced by ZIKV infection.
CONCLUSIONS: These findings suggest that TF2b has a potent antiviral effect and can be used as a potential candidate for the treatment of ZIKV infection.